Literature DB >> 10454340

Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease.

D Conte1, M Fraquelli, F Capsoni, M Giacca, L Zentilin, M T Bardella.   

Abstract

In chronic granulomatous disease, interferon-gamma (IFN-gamma) significantly reduces the incidence and severity of recurrent infections, but its effectiveness administered ex novo during acute infection has been reported in only one case. In this report, we describe two adult brothers with chronic granulomatous disease treated successfully with IFN-gamma for acute liver abscesses. Two brothers with severe recurrent infections of unknown origin were hospitalized for septic fever, malnutrition, and ultrasonographic evidence of liver abscess. Autosomal recessive chronic granulomatous disease was diagnosed based on lack of superoxide anion production by phagocytes and absence of p47-phox protein. An antibiotic regimen specifically directed against Staphylococcus aureus was ineffective, whereas treatment with 50 microg/m2 IFN-gamma s.c. thrice weekly induced complete healing with scarring within 3 months. No septic recurrence was observed during a 4-year follow-up period. In chronic granulomatous disease, IFN-gamma is effective not only in preventing but also in healing life-threatening acute infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454340     DOI: 10.1089/107999099313541

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  2 in total

Review 1.  Infectious Complications in Patients With Chronic Granulomatous Disease.

Authors:  Nicholas Bennett; Paul J Maglione; Benjamin L Wright; Christa Zerbe
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164

2.  MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity.

Authors:  Netanya S Utay; Annelys Roque; J Katherina Timmer; David R Morcock; Claire DeLeage; Anoma Somasunderam; Amy C Weintrob; Brian K Agan; Jacob D Estes; Nancy F Crum-Cianflone; Daniel C Douek
Journal:  PLoS Pathog       Date:  2016-04-19       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.